Glioblastoma Multiforme is most aggressive cancer
Glioblastoma Multiforme or GBM is the most common type of malignant (cancerous) primary brain tumor and often forms in the cerebral hemisphere of the brain. Glioblastomas are formed from mutated astrocytes, which are cells that begin to reproduce uncontrollably and are supplied generously via nearby blood vessels. Glioblastomas are derived from healthy brain cells and are capable of living and growing within the cerebral cavity.
Glioblastomas take on two forms, primary and secondary, which are distinguished by their rate of growth. Primary glioblastomas form rapidly and are very aggressive. Secondary glioblastomas form at slower rates, transforming from initially benign lesions into aggressive tumors. Patients with glioblastoma often experience a persistent headache, nausea, drowsiness, and vomiting. Depending on the size and location of the tumor, additional symptoms can include weakness, memory loss, and speech impairment. Glioblastoma is diagnosed by a neurologist or neurological surgeon following diagnostic imaging. Typically, patients have undergone a Computed Tomography (CT) scan of the head showing a lesion in the brain. Magnetic resonance imaging (MRI) is then obtained to identify more precisely the size, shape, location, and type of the brain tumor.
By Hexaresearch Report The global glioblastoma multiforme (GBM) market is fueled by the increasing occurrence of cancer in the central nervous system among the aging population. The market is highly prevalent in the countries of North America and Europe region.
Apart from North America and Europe, instances of glioblastoma are prevalent in the Asia Pacific as well. To that end, Japan is one of the countries with a relative prevailing rate of glioblastoma owing to the presence of a high number of elderly individuals.
The disease is characterized as one of the most aggressive cancer which usually recurs periodically. Typically, a person suffering from glioblastoma survives for around one year, with a marginal survival rate of 3%-5% over five years.
Rising aging population along with increasing awareness of novel therapies has added to the growth of the GBM market. The tumor continues to grow increasing with age, peaking between 75 to 84 years of age and then declines after 85 years.
In 2016, North America contributed to 39.2% of the global glioblastoma multiforme market share and is expected to witness steady growth over the forecast period. Substantial spending on the healthcare sector has resulted in the maturity of the treatment for the disease. U.S remained one of the leading GBM markets in the region.
Asia Pacific is expected to be the fastest-growing market over the forecast period and is expected to be valued over USD 270 million by 2024. A high incidence rate of glioblastoma in Japan and China is expected to drive the market for its treatment solutions.
Companies are focusing on research and development in molecular biotechnology and gene therapy related to the central nervous system and cancer. This advancement may provide an improvement in innovative possibilities for effective treatment of GBM over the forecast period.
Biologic products present a unique opportunity for focal treatment of GBM. Focal treatment techniques present an effective and feasible treatment option for those suffering from GBM. With biologic products, the focus is on treating the tumor at a cellular or molecular level. These factors together are expected to contribute to the growth of the GBM market over the next few years.
Access full report or request for a free sample at: https://www.hexaresearch.com/research-report/glioblastoma-multiforme-gbm-market